Effect of mopidamol on survival in carcinoma of the lung and colon: Final report of veterans administration cooperative study no. 188

Leo R. Zacharski, Thomas E. Moritz, Linda A. Baczek, Frederick R. Rickles, Richard L. Edwards, Walter B. Forman, R. Jackson Forcier, C. J. Cornell, Clair M. Haakenson, Harold S. Ballard, Edward D. Crum, Gerhard J. Johnson, James Levine, Waun Ki Hong, Joseph F. O'donnell, Richard L. Schilsky, Q. Scott Ringenberg, Francisco Robert, Monica B. Spaulding, Karl TornyosCharles Williams, Stanley Zucker, Charles S. Faulkner, Walter L. Eaton, Charles L. Hoppel

Research output: Contribution to journalArticlepeer-review

46 Scopus citations

Abstract

Mopidamol (RA-233), a derivative of dipyridamole, is a phosphodiesterase inhibitor that has been shown previously to limit progression of malignancy in certain experimental animal models and in a pilot study in humans. RA-233 plus chemotherapy was compared with chemotherapy alone in a 5-year double-blind trial involving 719 patients with advanced carcinomas of the lung and of the colon. RA-233 treatment was associated with a statistically significant prolongation of survival in patients with non-small cell lung cancer (N-SCLC) limited to one hemithorax and with reduction in mean plasma fibrogen concentration. RA-233 was not toxic. The favorable effects on survival could not be explained by any factor other than the RA-233 treatment. In other tumor categories tested, no differences in survival were observed. These results suggest that RA-233 is useful in the treatment of N-SCLC of limited extent. They also suggest that therapeutic intervention aimed at modified intracellular pathways might constitute a novel investigative approach to the treatment of cancer.

Original languageEnglish (US)
Pages (from-to)90-97
Number of pages8
JournalJournal of the National Cancer Institute
Volume80
Issue number2
DOIs
StatePublished - Mar 16 1988

Bibliographical note

Funding Information:
This work was supported by the VA Cooperative Studies Program, Medical Research Service, VA Central Office, Washington, DC.

Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.

Fingerprint Dive into the research topics of 'Effect of mopidamol on survival in carcinoma of the lung and colon: Final report of veterans administration cooperative study no. 188'. Together they form a unique fingerprint.

Cite this